Thymosin Alpha-1

A 28-amino acid peptide originally isolated from thymic tissue by Allan Goldstein in the 1970s. FDA orphan drug and approved in over 35 countries for hepatitis B/C and as an immune adjuvant. Considered the gold standard immune-modulating peptide.

• Stimulates T-cell progenitor differentiation via thymic pathways
• Upregulates MHC class I expression on antigen-presenting cells
• Increases IL-2 and interferon-alpha production
• Enhances toll-like receptor signaling in dendritic cells
• Promotes CD4+ and CD8+ T-cell activation and proliferation

• Organ transplant recipients on immunosuppressants
• Active autoimmune flare (may exacerbate)
• Pregnancy or breastfeeding

Store at 2–8°C (36–46°F) for up to 6 months. Once reconstituted, use immediately or within 24 hours refrigerated. Also available as Zadaxin in prefilled syringes.

Approved in over 35 countries for chronic hepatitis B/C and as a vaccine adjuvant. Granted FDA orphan drug designation. Extensive clinical trial data including Phase 3 studies in hepatitis and Phase 2 studies as cancer immunotherapy adjunct. SciClone Pharmaceuticals conducted large-scale RCTs demonstrating improved viral clearance and immune reconstitution.